GSK and Vir Biotechnology's Sotrovimab (Xevudy®) (VIR-7831, GSK4182136)

The Sotrovimab antibody therapy is designed to bind to an epitope on the SARS-CoV-2 coronavirus to neutralize it.

Sotrovimab was derived from a parent antibody (S309), first isolated in 2003 from memory B cells taken from an individual who had recovered from the SARS-1. In April 2020, Vir Biotechnology, Inc. and GSK announced a collaboration to research and develop Vir's proprietary monoclonal antibody platform technology to accelerate existing and identify new antiviral antibodies.

Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the investigational monoclonal antibody therapeutic was granted on May 26, 2021

U.S.A. purchased 1.7 million doses